nejm tirzepatide osa #Mounjaro/#zepbound (tirzepatide) for obesity complicated by sleep apnea trials presented at #ADA2024 and published in @nejm1️⃣ Participants who were not receiving treatment with positive airway Tirzepatide Demonstrates Reduction in Sleep

95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points

Delayed gastric transit Worsening nausea and vomiting Increased risk of malnutrition 11

Cagrilintide vs Semaglutide: Which GLP-1 Peptide Is Better for Weight Loss

Sometimes an antidepressant if indicated, chosen carefully to avoid metabolic side effects

10.1016/j.freeradbiomed.2020.02.027 68 Usategui-MartnR.Puertas-NeyraK.Galindo-CabelloN.Hernndez-RodrguezL

Holst Lange declined to provide more specific data on the differences observed between REDEFINE 1, which was one of two studies that made up the FDA application, and REDEFINE 4, but said the weight loss achievement was similar in both studies